Retatrutide (LY3437943) record · updated 8h ago
Metabolic & appetiteSkin & aestheticsGrade D · emergingResearch use only
What is Retatrutide (LY3437943) used for?
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
How it works: Triple GLP-1 / GIP / glucagon receptor agonist
Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection
Development stage
where Retatrutide (LY3437943) sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus and 18 registered trials. It describes the research record, not a recommendation.
Identity
NameRetatrutide (LY3437943)
Full name—
Sequence—
ClassWeight Loss
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismTriple GLP-1 / GIP / glucagon receptor agonist
RouteSubcutaneous injection
Half-life~6 days
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.75
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies0
Human / animal / cellular0 / 0 / 0
Highest trial phase—
Years covered2026–2026
Latest study—
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records
| Study | Type | Year | Summary depth |
|---|---|---|---|
| No approved studies filed yet — the Librarian is still searching. | |||
Articles mentioning Retatrutide (LY3437943)
- Mounjaro vs Ozempic: Tirzepatide vs Semaglutide, Brand by BrandMounjaro is Tirzepatide; Ozempic is Semaglutide. Different molecules, different mechanisms, different effect sizes. Here's the brand-level comparison plus insurance and pen-format differences.comparison · 4 min
- Best Peptides for Fat Loss: Evidence-Based RoundupRanked roundup of peptides studied for fat loss — GLP-1 / GIP agonists, GH-axis fragments, and supporting metabolic peptides — with mechanism, evidence quality, and how to choose.weight-loss · 6 min
- Cagrilintide Explained: Amylin Agonist + CagriSema CombinationCagrilintide (AM833) is Novo Nordisk's long-acting amylin receptor agonist. Combined with Semaglutide it produces ~17–22% weight loss in Phase 3 trials with a different mechanism than GLP-1.news · 4 min
- Retatrutide Explained: The Triple-Receptor Weight-Loss Drug in Phase 3Retatrutide (LY3437943) is a GLP-1 + GIP + glucagon triple receptor agonist producing ~24% weight loss at 48 weeks in Phase 2 trials. Here's what it is, how it works, and where it stands.news · 4 min
- Semaglutide vs Tirzepatide: Mechanism, Trial Data, Which to ChooseSemaglutide vs Tirzepatide — head-to-head on mechanism (GLP-1 vs GIP+GLP-1), Phase 3 weight loss (~15% vs ~21%), side effects, cardiovascular evidence, and how to choose.comparison · 6 min
- Tirzepatide vs Retatrutide: Dual vs Triple Receptor AgonismTirzepatide is FDA-approved GIP+GLP-1 dual agonism (~21% weight loss). Retatrutide is GLP-1+GIP+glucagon triple agonism in Phase 3 (~24% Phase 2). Here's how they compare.comparison · 5 min
- Peptide Stack for Weight Loss: Defensible CombinationsWhat 'peptide stack for weight loss' actually means — the defensible combinations (CagriSema, GLP-1 + Tesamorelin, GLP-1 + healing peptides), what to avoid, and why training plus protein is the load-bearing partner.stack · 5 min